Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xuping Xie, Antonio E. Muruato, Xianwen Zhang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223

Showing 26-50 of 223 citing articles:

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective
Mona Seifert, Subhas Chandra Bera, Pauline van Nies, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 64
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Jared Pitts, Jiani Li, Jason K. Perry, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 60
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Choosing a cellular model to study SARS-CoV-2
Gabriel Augusto Pires de Souza, Marion Le Bideau, Céline Boschi, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 42
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Richard L. Mackman, Rao Kalla, Darius Babusis, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 11701-11717
Open Access | Times Cited: 29
Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
Daniele Focosi, Fabrizio Maggi, Paola Mazzetti, et al.
Reviews in Medical Virology (2020) Vol. 31, Iss. 2
Open Access | Times Cited: 57
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
Thuc Nguyen Dan, Kim Donckers, Laura Vangeel, et al.
Antiviral Research (2021) Vol. 192, pp. 105122-105122
Open Access | Times Cited: 54
Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes
Kevin Chiem, Desarey Morales Vasquez, Jun‐Gyu Park, et al.
Journal of Virology (2021) Vol. 95, Iss. 7
Open Access | Times Cited: 52
Advances in Neutralization Assays for SARS‐CoV‐2
Yuying Lu, Wang Jin, Qianlin Li, et al.
Scandinavian Journal of Immunology (2021) Vol. 94, Iss. 3
Open Access | Times Cited: 51
Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells
Ruidong Li, Albert Liclican, Yili Xu, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 9
Open Access | Times Cited: 50
Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies
Jianfu J. Wang, Nan Zhang, SARAH RICHARDSON, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 21, Iss. 4, pp. 363-370
Open Access | Times Cited: 46
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
Jiashu Xie, Zhengqiang Wang
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 6, pp. 1607-1616
Open Access | Times Cited: 45
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
Ross Martin, Jiani Li, Aiyappa Parvangada, et al.
Antiviral Research (2021) Vol. 188, pp. 105033-105033
Open Access | Times Cited: 43
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
Matthew D. Hall, James M. Anderson, Annaliesa S. Anderson, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. Supplement_1, pp. S1-S21
Open Access | Times Cited: 41
Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19
Jacqueline Venturas, Jarrod Zamparini, Erica Shaddock, et al.
Journal of Infection (2021) Vol. 83, Iss. 2, pp. 217-227
Open Access | Times Cited: 40
Functions of Coronavirus Accessory Proteins: Overview of the State of the Art
Puxian Fang, Liurong Fang, Huichang Zhang, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 1139-1139
Open Access | Times Cited: 40
Selection of a SARS-CoV-2 Surrogate for Use in Surface Disinfection Efficacy Studies with Chlorine and Antimicrobial Surfaces
Gabrielle String, Mitchell R. White, David M. Gute, et al.
Environmental Science & Technology Letters (2021) Vol. 8, Iss. 11, pp. 995-1001
Open Access | Times Cited: 40
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
Iart Luca Shytaj, Mohamed Fares, Lara Gallucci, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 35
Allosteric inhibitors of the main protease of SARS-CoV-2
Subodh Kumar Samrat, Jimin Xu, Xuping Xie, et al.
Antiviral Research (2022) Vol. 205, pp. 105381-105381
Open Access | Times Cited: 35
A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection
Pehuén Pereyra Gerber, Lidia M. Duncan, Edward JD Greenwood, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 2, pp. e1010265-e1010265
Open Access | Times Cited: 34
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
Richard L. Mackman
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 338-347
Open Access | Times Cited: 31
A simple reverse genetics method to generate recombinant coronaviruses
Julien Mélade, Géraldine Piorkowski, Franck Touret, et al.
EMBO Reports (2022) Vol. 23, Iss. 5
Open Access | Times Cited: 30
Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
Ariana Ghez Farrell, Bernadeta Dadonaite, Allison J. Greaney, et al.
Viruses (2022) Vol. 14, Iss. 9, pp. 2061-2061
Open Access | Times Cited: 29
Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
Ulrik Fahnøe, Long V. Pham, Carlota Fernandez-Antunez, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 172-172
Open Access | Times Cited: 28

Scroll to top